ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)

项目摘要 拟议的白血病转化科学中心（LTSC）将产生，协调和领导翻译 ECOG-ACRIN和国家临床试验网络（NCTN）内的白血病研究。LTSC将 作为白血病实验室委员会（LLC）研究的中心枢纽， 白血病转化实验室（LTRL）和白血病组织库（LTB），以及一个全面的 白血病数据仓库。LTSC由R. Levine，A. Melnick和A.费兰多他们已经开发 在翻译研究领导和实施最先进的相关技术方面有着广泛的记录 白血病生物学的研究。LTSC通过与MSK中心的合作进一步加强， 分子肿瘤学和血液肿瘤中心，提供高通量 基因组学技术，最先进的基因组平台，计算资源，以及 进行广泛的CLIA认证的临床基因组学分析。为了最大限度地加快高质量 基于最重要科学的临床试验，LTSC将建立一个互动框架， 吸引初级和高级临床研究人员、实验室科学家、计算生物学家、生物统计学家 和其他人，并使他们能够形成协同研究团队。LTSC将提供试点项目资金， 跨学科团队来启动这些项目和广泛的科学资源，包括 访问患者样本和临床/分子数据，基因组和表观遗传分析能力， 分析平台，科学支持和强大的，富有成效的协作白血病研究社区。在 通过这种方式，LTSC将确保转化科学研究与白血病无缝结合 临床试验，以确定反应/结果的预测因素，确定和测试新的治疗方法，并开发 创新的相关研究，以评估抗白血病治疗的反应。通过这些活动， LTSC旨在通过制定和实施 个性化诊断方法、生物标志物和疗法。

PROJECT SUMMARY The proposed Leukemia Translational Science Center (LTSC), will generate, coordinate and lead translational studies in leukemia within ECOG-ACRIN and within the National Clinical Trials Network (NCTN). The LTSC will serve as the central hub for studies of the Leukemia Laboratory Committee (LLC), with the support of the Leukemia Translational Laboratory (LTRL) and the Leukemia Tissue Bank (LTB), and a comprehensive Leukemia Data Warehouse. The LTSC is led by R. Levine, A. Melnick, and A. Ferrando. They have developed an extensive track record in translational research leadership and implementation of state-of-the-art correlative studies in leukemia biology. The LTSC is further enhanced through its partnership with the MSK Centers for Molecular Oncology and Center for Hematologic Malignancies, which provide access to high-throughput genomics technologies, state-of-the-art genomic platforms, computational resources, and the capability to perform extensive, CLIA-certified, clinical genomics assays. In order to maximally accelerate high quality clinical trials based on the most important science, the LTSC will establish an interaction framework that will attract junior and senior clinical investigators, laboratory scientists, computational biologists, biostatisticians and others, and enable them to form synergistic research teams. The LTSC will provide pilot project funding for cross-disciplinary teams to jump-start these projects and an extensive suite of scientific resources, including access to patient samples and clinical/molecular data, genomic and epigenetic profiling capabilities and analytic platforms, scientific support, and a robust, productive collaborative leukemia research community. In this way, the LTSC will ensure that translational scientific studies are seamlessly integrated into leukemia clinical trials to identify predictors of response/outcome, identify and test novel therapies, and develop innovative correlative studies to assess response to anti-leukemia therapies. Through these activities, the LTSC aims to transform the standard practice of leukemia care with the development and implementation of personalized diagnostic methods, biomarkers and therapies.